Effect of iTBS on Children With ADHD

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Aug 24, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called intermittent Theta Burst Stimulation (iTBS) on children with Attention Deficit/Hyperactivity Disorder (ADHD). ADHD is a common condition that causes difficulties with paying attention and controlling impulses. The trial aims to see if iTBS can help improve attention in children aged 6 to 12 who have been diagnosed with ADHD for more than six months. Unlike some traditional medications that can have side effects and risks of misuse, this study explores a different approach to help these children.

To be eligible for the trial, children must be between 6 and 12 years old, right-handed, and diagnosed with ADHD according to specific guidelines. They should also have an intelligence score of 70 or higher. However, children with other mental health issues, serious medical conditions, or those who have had certain treatments recently may not qualify. Participants will receive iTBS treatment on weekends and will undergo evaluations and brain scans before and after the treatment to see how well it works. This study is important because it could offer a new option for managing ADHD symptoms without the risks associated with some medications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of ADHD in accordance with DSM-V;
• • Age 6-12 years old, regardless of gender
• • Right-handed
• • Han nationality or born in the Han nationality Ghetto
• • The course of the disease is greater than 6 months
• • Webster children's intelligence ≥ 70
• • The patient's guardian agrees and signs an informed consent form.
• Exclusion Criteria:
• • Concomitant mental disorders such as anxiety and depression;
• • Widespread developmental disorders and other neurological developmental related disorders;
• • Complication with other important organ diseases such as heart and lungs;
• • Suffering from diseases such as epilepsy and tic disorder;
• • Individuals who cannot tolerate rTMS treatment or cannot cooperate with treatment.
• • Patients taking psychoactive drugs, antipsychotics, antidepressants, or mood stabilizers 3 months prior to enrollment or during rTMS treatment; In addition to the minimum effective therapeutic dose of Tomoxetine (1.2-1.4 mg • kg/day), there has been systematic use of first-line ADHD drugs in clinical practice Webster's intelligence\<70
• • Implantation of metal and electronic components in the body (excluding the oral cavity), such as pacemakers;